NOT FOR DISTRIBUTION
Header cover image

Heilongjiang ZBD Pharmaceutical

Market Cap

CN¥11.5b

Last Updated

2021/04/17 09:14 UTC

Data Sources

Company Financials

Executive Summary

Heilongjiang ZBD Pharmaceutical Co., Ltd. More Details


Snowflake Analysis

Mediocre balance sheet unattractive dividend payer.

Share Price & News

How has Heilongjiang ZBD Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 603567 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 603567's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-2.3%

603567

-2.8%

CN Pharmaceuticals

-0.8%

CN Market


1 Year Return

8.7%

603567

10.4%

CN Pharmaceuticals

25.0%

CN Market

Return vs Industry: 603567 underperformed the CN Pharmaceuticals industry which returned 10.4% over the past year.

Return vs Market: 603567 underperformed the CN Market which returned 25% over the past year.


Shareholder returns

603567IndustryMarket
7 Day-2.3%-2.8%-0.8%
30 Day5.2%1.0%-0.08%
90 Day28.8%-5.1%-5.3%
1 Year10.7%8.7%11.5%10.4%27.0%25.0%
3 Year7.3%2.7%25.2%20.8%29.1%22.8%
5 Year-25.2%-29.9%46.5%38.7%30.5%21.7%

Long-Term Price Volatility Vs. Market

How volatile is Heilongjiang ZBD Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Heilongjiang ZBD Pharmaceutical undervalued compared to its fair value and its price relative to the market?

36.79x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 603567 (CN¥13.46) is trading above our estimate of fair value (CN¥4.33)

Significantly Below Fair Value: 603567 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 603567 is poor value based on its PE Ratio (36.8x) compared to the CN Pharmaceuticals industry average (31.9x).

PE vs Market: 603567 is poor value based on its PE Ratio (36.8x) compared to the CN market (33.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 603567's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 603567 is good value based on its PB Ratio (2.2x) compared to the CN Pharmaceuticals industry average (2.7x).


Future Growth

How is Heilongjiang ZBD Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Heilongjiang ZBD Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Heilongjiang ZBD Pharmaceutical performed over the past 5 years?

-9.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 603567 has a large one-off gain of CN¥117.6M impacting its September 30 2020 financial results.

Growing Profit Margin: 603567's current net profit margins (10.5%) are lower than last year (14.6%).


Past Earnings Growth Analysis

Earnings Trend: 603567's earnings have declined by 9.5% per year over the past 5 years.

Accelerating Growth: 603567's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 603567 had negative earnings growth (-27.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10.3%).


Return on Equity

High ROE: 603567's Return on Equity (5.8%) is considered low.


Financial Health

How is Heilongjiang ZBD Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: 603567's short term assets (CN¥5.9B) exceed its short term liabilities (CN¥1.3B).

Long Term Liabilities: 603567's short term assets (CN¥5.9B) exceed its long term liabilities (CN¥2.8B).


Debt to Equity History and Analysis

Debt Level: 603567's debt to equity ratio (58.4%) is considered high.

Reducing Debt: 603567's debt to equity ratio has increased from 19.1% to 58.4% over the past 5 years.

Debt Coverage: 603567's debt is not well covered by operating cash flow (2.2%).

Interest Coverage: 603567 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Heilongjiang ZBD Pharmaceutical current dividend yield, its reliability and sustainability?

1.61%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 603567's dividend (1.61%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).

High Dividend: 603567's dividend (1.61%) is low compared to the top 25% of dividend payers in the CN market (1.79%).


Stability and Growth of Payments

Stable Dividend: 603567 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 603567 has only been paying a dividend for 5 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (59.3%), 603567's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

CN¥624k

CEO Compensation


CEO

Tong Hua Fang

no data

Tenure

CN¥623,700

Compensation

Mr. Tong Hua Fang serves as the Chairman and General Manager at Heilongjiang ZBD Pharmaceutical Co., Ltd.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heilongjiang ZBD Pharmaceutical Co., Ltd.
  • Ticker: 603567
  • Exchange: SHSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥11.459b
  • Shares outstanding: 849.16m
  • Website: https://www.zbdzy.com

Number of Employees


Location

  • Heilongjiang ZBD Pharmaceutical Co., Ltd.
  • No. 72 Hongxing Street
  • Hulin
  • China

Listings


Biography

Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthope...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/17 09:14
End of Day Share Price2021/04/16 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.